Nitrendipine shortage leaves hypertension patients scrambling for alternatives

Patients relying on nitrendipine, a widely used calcium channel blocker, have faced ongoing supply issues since last summer. The shortages now affect both the 10 mg and 20 mg formulations, leaving manufacturers unable to meet demand. Regulatory bodies and pharmaceutical companies have begun addressing the problem, but full recovery remains months away.

Nitrendipine belongs to a class of drugs called calcium channel blockers, which work by preventing calcium from entering cells. This action keeps arteries relaxed, lowers blood pressure, and slows cardiac conduction. The medication falls under the nifedipine-type group, one of three categories of calcium channel blockers, each with distinct effects and applications.

Supply bottlenecks have hit nitrendipine particularly hard, with Aristo reporting production problems that will last until the end of 2023. Germany's Federal Institute for Drugs and Medical Devices (BfArM) has officially listed the drug among current shortages. While Ratiopharm and Aliud Pharma plan to resume 20 mg deliveries by the end of March, AbZ expects to restart supply only by late May. In response to the shortage, doctors have increasingly turned to alternatives like amlodipine, felodipine, lercanidipine, and nifedipine—all within the same drug class. These substitutes share similar mechanisms but may differ in dosage timing, which can vary by medication. Some require administration with meals, others after, and maintaining a consistent schedule is essential for effectiveness. Common side effects of calcium channel blockers include low blood pressure, headaches, flushing, and palpitations. Patients switching medications may experience these reactions, though individual responses can differ.

The nitrendipine shortage has forced healthcare providers to rely on alternative treatments for high blood pressure and related conditions. With supply disruptions expected to persist for months, manufacturers and regulators continue working to stabilise availability. Patients are advised to consult their doctors before making any changes to their medication routines.